Cytokinetics Inc (CYTK) stock

CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30

$56.13−0.03 (-0.05%)

Close on Nov 13, 2026Market cap $7.80BP/E –Yield –

Cytokinetics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Cytokinetics's EV/EBITDA was 45.7× on Jul 31, 2017, against 4.5× a year earlier.

Period	Period end	Value	Change (pts)
2017	Jul 31, 2017	45.7×	−118.9
2016	Dec 30, 2016	164.6×	+161.6
2011	Jan 31, 2011	3.0×	−0.4
2010	Dec 31, 2010	3.4×	–

Parsed from the XBRL in Cytokinetics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-6 reverse split on Jun 25, 2013
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing